
Matthew John Kasztejna
Examiner (ID: 13619, Phone: (571)272-6086 , Office: P/3779 )
| Most Active Art Unit | 3779 |
| Art Unit(s) | 3795, 3779, 3739, 3993, 3799 |
| Total Applications | 1245 |
| Issued Applications | 699 |
| Pending Applications | 148 |
| Abandoned Applications | 418 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20386573
[patent_doc_number] => 12486290
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-02
[patent_title] => Isoindolinone and indazole compounds for the degradation of EGFR
[patent_app_type] => utility
[patent_app_number] => 19/205510
[patent_app_country] => US
[patent_app_date] => 2025-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 134503
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 386
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19205510
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/205510 | Isoindolinone and indazole compounds for the degradation of EGFR | May 11, 2025 | Issued |
Array
(
[id] => 19682247
[patent_doc_number] => 20250000792
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS
[patent_app_type] => utility
[patent_app_number] => 18/883447
[patent_app_country] => US
[patent_app_date] => 2024-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46548
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18883447
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/883447 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Sep 11, 2024 | Pending |
Array
(
[id] => 19629609
[patent_doc_number] => 20240408058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/809240
[patent_app_country] => US
[patent_app_date] => 2024-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36906
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 279
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18809240
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/809240 | COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS | Aug 18, 2024 | Pending |
Array
(
[id] => 19599465
[patent_doc_number] => 20240390345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
[patent_app_type] => utility
[patent_app_number] => 18/795731
[patent_app_country] => US
[patent_app_date] => 2024-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795731
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/795731 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Aug 5, 2024 | Issued |
Array
(
[id] => 19599463
[patent_doc_number] => 20240390343
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
[patent_app_type] => utility
[patent_app_number] => 18/795683
[patent_app_country] => US
[patent_app_date] => 2024-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26127
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795683
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/795683 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Aug 5, 2024 | Issued |
Array
(
[id] => 19777386
[patent_doc_number] => 12226406
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
[patent_app_type] => utility
[patent_app_number] => 18/795711
[patent_app_country] => US
[patent_app_date] => 2024-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26142
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795711
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/795711 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Aug 5, 2024 | Issued |
Array
(
[id] => 20082956
[patent_doc_number] => 20250212892
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-03
[patent_title] => USE OF THERMALLY HYDROLYZED KERATIN PEPTIDE SOLUTION IN ENHANCING THE YIELD AND QUALITY OF TEA LEAVES
[patent_app_type] => utility
[patent_app_number] => 18/758140
[patent_app_country] => US
[patent_app_date] => 2024-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758140
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/758140 | USE OF THERMALLY HYDROLYZED KERATIN PEPTIDE SOLUTION IN ENHANCING THE YIELD AND QUALITY OF TEA LEAVES | Jun 27, 2024 | Pending |
Array
(
[id] => 19947036
[patent_doc_number] => 12318374
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
[patent_app_type] => utility
[patent_app_number] => 18/758007
[patent_app_country] => US
[patent_app_date] => 2024-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21900
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758007
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/758007 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | Jun 27, 2024 | Issued |
Array
(
[id] => 19510497
[patent_doc_number] => 20240342183
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/752293
[patent_app_country] => US
[patent_app_date] => 2024-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 212
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18752293
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/752293 | LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF | Jun 23, 2024 | Pending |
Array
(
[id] => 19768275
[patent_doc_number] => 20250049701
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => SILK-BASED ARTICLES HAVING VARIABLE ACTIVE AGENT RELEASE RATES
[patent_app_type] => utility
[patent_app_number] => 18/746604
[patent_app_country] => US
[patent_app_date] => 2024-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10933
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18746604
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/746604 | SILK-BASED ARTICLES HAVING VARIABLE ACTIVE AGENT RELEASE RATES | Jun 17, 2024 | Pending |
Array
(
[id] => 19510401
[patent_doc_number] => 20240342087
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => TARGETED EXTRACELLULAR VESICLES COMPRISING MEMBRANE PROTEINS WITH ENGINEERED GLYCOSYLATION SITES
[patent_app_type] => utility
[patent_app_number] => 18/731681
[patent_app_country] => US
[patent_app_date] => 2024-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731681
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/731681 | TARGETED EXTRACELLULAR VESICLES COMPRISING MEMBRANE PROTEINS WITH ENGINEERED GLYCOSYLATION SITES | Jun 2, 2024 | Pending |
Array
(
[id] => 19570268
[patent_doc_number] => 20240374560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => FIBER-ENHANCED LIPOSOME AND METHODS
[patent_app_type] => utility
[patent_app_number] => 18/662189
[patent_app_country] => US
[patent_app_date] => 2024-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9430
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18662189
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/662189 | FIBER-ENHANCED LIPOSOME AND METHODS | May 12, 2024 | Pending |
Array
(
[id] => 19379448
[patent_doc_number] => 20240269318
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/626620
[patent_app_country] => US
[patent_app_date] => 2024-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626620
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/626620 | NANO-DELIVERY SYSTEMS COMPRISING MODIFIED LIPIDS AND USE THEREOF | Apr 3, 2024 | Pending |
Array
(
[id] => 19331283
[patent_doc_number] => 20240245713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => LONG-ACTING INJECTABLE FORMULATIONS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/626241
[patent_app_country] => US
[patent_app_date] => 2024-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8360
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626241
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/626241 | LONG-ACTING INJECTABLE FORMULATIONS AND USE THEREOF | Apr 2, 2024 | Pending |
Array
(
[id] => 19279801
[patent_doc_number] => 20240216273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => TOPICAL ANESTHETIC
[patent_app_type] => utility
[patent_app_number] => 18/608602
[patent_app_country] => US
[patent_app_date] => 2024-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18608602
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/608602 | TOPICAL ANESTHETIC | Mar 17, 2024 | Pending |
Array
(
[id] => 19446514
[patent_doc_number] => 20240306644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => STABLE CHLORINATED ALKALINE PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 18/606407
[patent_app_country] => US
[patent_app_date] => 2024-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5264
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606407
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/606407 | STABLE CHLORINATED ALKALINE PRODUCTS | Mar 14, 2024 | Pending |
Array
(
[id] => 19554694
[patent_doc_number] => 20240366486
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => HYDROPHOBIC SYNTHETIC MELANIN NANOPARTICLES
[patent_app_type] => utility
[patent_app_number] => 18/601746
[patent_app_country] => US
[patent_app_date] => 2024-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53919
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601746
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/601746 | HYDROPHOBIC SYNTHETIC MELANIN NANOPARTICLES | Mar 10, 2024 | Pending |
Array
(
[id] => 19570494
[patent_doc_number] => 20240374786
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => NANOFIBER AND MICROFIBER HYBRID AEROGELS
[patent_app_type] => utility
[patent_app_number] => 18/600263
[patent_app_country] => US
[patent_app_date] => 2024-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19992
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600263
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | Mar 7, 2024 | Pending |
Array
(
[id] => 19263462
[patent_doc_number] => 20240207159
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => SKIN PENETRATION IMPROVER
[patent_app_type] => utility
[patent_app_number] => 18/589817
[patent_app_country] => US
[patent_app_date] => 2024-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5352
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589817
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/589817 | SKIN PENETRATION IMPROVER | Feb 27, 2024 | Pending |
Array
(
[id] => 19246700
[patent_doc_number] => 20240197684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS
[patent_app_type] => utility
[patent_app_number] => 18/443689
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98483
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 143
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443689
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443689 | Non-sedating dexmedetomidine treatment regimens | Feb 15, 2024 | Issued |